Here are the 10-K annual reports from Dianthus Therapeutics, Inc. (DNTH) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow DNTH and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full DNTH filings page.
Dianthus Therapeutics, Inc. files its annual report describing a clinical-stage pipeline focused on severe autoimmune diseases and complement biology. The company’s market value held by non-affiliates was $599.4 million based on its common stock closing price on June 30, 2025, with 44,471,094 shares outstanding as of March 4, 2026.
Dianthus’ lead antibody, claseprubart, targets active C1s in the classical complement pathway and is being tested in mid‑ to late‑stage trials in generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy. A Phase 2 gMG study showed statistically significant and clinically meaningful improvements versus placebo on multiple endpoints with a safety profile comparable to placebo.
The company is advancing a planned global Phase 3 gMG trial, a pivotal Phase 3 CIDP trial that met an early responder target, and a Phase 2 MMN trial. Dianthus also licensed DNTH212, a bifunctional BDCA2 and BAFF/APRIL inhibitor, for development outside Greater China, with a Phase 1 study underway. The report outlines extensive IP protection, third‑party manufacturing arrangements, regional licensing with Tenacia and Leads, competitive dynamics in gMG, CIDP and MMN, and detailed U.S. and global regulatory frameworks for biologics.